2 Bridge is proud to be a partner of the Cell and Gene Therapy Accelerator Program, newly launched by Brussels South Charleroi BioPark (BSCB). The #AcceleratorProgram serves to de-risk early-stage research and build the advanced therapy companies of the future.
Open to #academic, #industry or independent researchers across Europe, this 12-18 month Program consists of an intensive boot camp, workshops and coaching, plus access to the Université libre de Bruxelles Open BioLab and state-of-the-art technology platforms. Moreover, up to €500,000 in funding per project can be awarded. In addition to 2 Bridge, other partners include #investors Sambrinvest, Theodorus Investment Funds and FundPlus, #industry players incl. UCB, BONE THERAPEUTICS S.A. and Ncardia, and service providers such as the European Patent Office, CMMI, GEVERS, and Nexelis.
In many ways, this Program reflects what 2 Bridge and its ecosystem stand for: together with investors, we advance #earlystage projects and efficiently bring tomorrow’s medicines to #patients. Building a #company and a #drugdevelopment program takes a (global) village, and we are happy our cross-functional teams can support this aspiring Program and its participants.
The call for #applications opens June 29 and ends mid August, with the Program starting around September 20. More information: https://lnkd.in/d4r_BeH. Don’t hesitate to apply to this great opportunity or share broadly within your network!